UNSPSC 51413907: Manozodil

This classification denotes a vasodilating agent with the molecular formula C10H16N2S, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier GZM2484VQ4, chemically known as 4,5,6,7-tetrahydro-2-methyl-5-((methylamino)methyl)benzothiazole but generally known as manozodil, which bears US NIH Compound Identifier 72110. European Medicines Agency schedules Manozodil in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB08645MIG. The term MANOZODIL is an International Non-Proprietary Name.

UNSPSC 51413907 Manozodil is a Commodity code covering pharmaceutical products, specifically emergency and acute-care medications sourced by state and local health and human services agencies, fire departments, and cooperative purchasing alliances. State and local governments acquire these medications for emergency medical services, hospital formularies, and public health programs through a mix of sealed-bid procurements, cooperative purchasing agreements, and market-intelligence RFIs. The buying bodies include municipal fire rescue departments (City of Tampa), state health agencies (Texas Health and Human Services Commission), and multistate cooperative purchasing organizations (Minnesota Multistate Cooperative Purchasing Alliance, or MMCAP). Scope varies from small, targeted acquisitions of specific formulations (such as Tampa's procurement of four medication line items for advanced life support) to broad, multi-vendor framework agreements supporting dozens of state and local member jurisdictions with comprehensive generic and OTC pharmaceutical catalogs.

Recent activity shows concentration in the South and Upper Midwest. The City of Tampa issued an IFB (Bid No. 26-P-00188) on April 24, 2026, for Advanced Life Support Medications including 370 units of Labetalol HCI, 1,810 units of Epinephrine, 330 units of Adenosine, and 1,020 units of Diltiazem, with a bid deadline of April 8, 2026, and an estimated contract value of $40,000.00; the award carries a one-year term with two optional one-year renewals and includes a 5 percent Small Local Business Enterprise (SLBE) bid discount. The Minnesota Department of Administration issued an RFP (S1070000015802) for generic multi-source pharmaceuticals and OTC products under MMCAP on January 20, 2026, with a proposal deadline of March 26, 2026, requiring products available by May 15, 2026, and effective July 1, 2026, across state and local facilities in Minnesota and Oregon; awards will be made to multiple vendors based on price competitiveness (75 percent weight) and administrative compliance. The Texas Health and Human Services Commission issued an RFI (HHS0017013) on April 3, 2026, to gather market intelligence on direct-to-manufacturer prescription fulfillment capabilities before issuing a formal RFP; no budget or award value was specified in this preliminary information-gathering phase.